<DOC>
	<DOCNO>NCT01796470</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability , pharmacodynamics entospletinib idelalisib . Participants enrol one follow hematological tumor type : chronic lymphocytic leukemia ( CLL ) , follicular lymphoma ( FL ) , mantle cell lymphoma ( MCL ) , diffuse large B-cell lymphoma ( DLBCL ) , non-FL indolent non-Hodgkin lymphoma ( iNHL ; include lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia [ LPL/WM ] , small lymphocytic lymphoma [ SLL ] , marginal zone lymphoma [ MZL ] ) .</brief_summary>
	<brief_title>Entospletinib Combination With Idelalisib Adults With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Diagnosis Bcell iNHL , DLBCL , MCL , CLL document medical record histology base criterion establish World Health Organization For institution Phase 3 Phase 4 protocol study idelalisib ( Zydelig® ; GS1101 ) ; subject malignancy study protocol must fail screening register screen failure respective idelalisib protocol Prior treatment lymphoid malignancy Presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy Discontinuation therapy treatment cancer ≥ 3 week start study drug All acute toxic effect prior antitumor therapy resolve Grade ≤ 1 start study drug Karnofsky performance status ≥ 60 Life expectancy least 3 month Key Known histological transformation iNHL CLL aggressive form NHL ( ie , Richter transformation ) Known active central nervous system leptomeningeal lymphoma Presence know intermediate highgrade myelodysplastic syndrome Current therapy agent reduce gastric acidity , include limited antacid , H2 inhibitor , proton pump inhibitor Evidence ongoing systemic bacterial , fungal , viral infection time start study drug Ongoing liver injury Ongoing recent hepatic encephalopathy Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease Ongoing alcohol drug addiction Pregnancy breastfeed History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy Concurrent participation investigational drug trial therapeutic intent Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GS-US-339-0103</keyword>
	<keyword>SYK inhibitor</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>GS-9973</keyword>
	<keyword>GS 9973</keyword>
	<keyword>GS-1101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>Cal-101</keyword>
	<keyword>Cal 101</keyword>
	<keyword>idelalisib</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>CLL</keyword>
	<keyword>MCL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>iNHL</keyword>
	<keyword>FL</keyword>
	<keyword>MZL</keyword>
	<keyword>LPL</keyword>
	<keyword>SLL</keyword>
	<keyword>WM</keyword>
	<keyword>Waldenström 's macroglobulinemia</keyword>
</DOC>